PD Dr. Markus Eckstein

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Institute of Pathology

Time dependency of adjuvant therapy in advanced head-and-necksquamous-cell-carcinoma of unknown primary (CUP)-patients (2021) Balk M, Rupp R, Grundtner P, Müller SK, Allner M, Traxdorf M, Eckstein M, et al. Conference contribution Impact of intraepithelial capillary loops and atypical vessels in confocal laser endomicroscopy for the diagnosis of laryngeal and hypopharyngeal squamous cell carcinoma (2021) Sievert M, Eckstein M, Mantsopoulos K, Müller SK, Stelzle F, Aubreville M, Oetter N, et al. Journal article Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer (2021) Muilwijk T, Akand M, Van Der Aa F, De Coninck V, Claessens M, Hente R, Eckstein M, et al. Journal article Tumor budding correlates with discohesive growth pattern, tumor invasiveness and is associated with worse survival of pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC) (2021) Eckstein M, Kimmel C, Bruendl J, Weber F, Denzinger S, Gierth M, Burger M, et al. Conference contribution Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling (2021) Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S, Wullich B, et al. Conference contribution Primary Results of the phase II CheckRad-CD8 Trial: First-Line Treatment of locally advanced Head and Neck Tumors with double Checkpoint Blockade and Radiotherapy dependent on intratumoral CD8+T-Cell Infiltration (2021) Hecht M, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Klautke G, Laban S, et al. Conference contribution Prospective Assessment of the Inflammation Parameters in Blood Counts and Blood Serum as prognostic/predictive Parameters for Treatment with Immune Checkpoint-Inhibitors (2021) Schweizer C, Haderlein M, Schubert P, Zhou J, Semrau S, Rutzner S, Gostian AO, et al. Conference contribution Krt20, krt5, esr1 and erbb2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer (2021) Jütte H, Reike M, Wirtz RM, Kriegmair M, Erben P, Tully K, Weyerer V, et al. Journal article Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+T-cell infiltration. (2021) Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, et al. Conference contribution Integration of spatial pd-l1 expression with the tumor immune microenvironment outperforms standard pd-l1 scoring in outcome prediction of urothelial cancer patients (2021) Weyerer V, Strissel P, Strick R, Sikic D, Geppert CI, Bertz S, Lange F, et al. Journal article, Original article